Alivus Life Sciences Ltd
Alivus Life Sciences Ltd (ALIVUS) last reported results for the quarter ended Jun 2026, with sales of ₹640 crore and net profit of ₹160 crore. The stock last traded at ₹1,374, a market capitalisation of ₹16,874 crore, on a P/E of 27.1. Over the past 52 weeks the stock has ranged between ₹819 and ₹1,495. Figures are as of 6 Oct 2026 and are not real time.
Alivus Life Sciences Ltd share price and key metrics
- Current price
- ₹1,374
- Market cap
- ₹16,874 cr
- Stock P/E
- 27.1
- Book value
- ₹271
- ROE
- 17.9%
- ROCE
- 23.8%
- Dividend yield
- 0.36%
- 52w high / low
- 1495/819
Metrics as of 6 Oct 2026. Not real time.
Track Alivus Life Sciences Ltd
Cruxal reads every Alivus Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Alivus Life Sciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 6%
- TTM
- 8%
- 10 Years
- %
- 5 Years
- 9%
- 3 Years
- 6%
- TTM
- 25%
- 10 Years
- %
- 5 Years
- 15%
- 3 Years
- 30%
- 1 Year
- 47%
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 19%
- Last Year
- 18%
Alivus Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹640 cr, up 6.3% from ₹602 cr a year earlier. Net profit was ₹160 cr, up 31.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating profit | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other income | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before tax | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net profit | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS (₹) | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | 13.04 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alivus Life Sciences Ltd annual results
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Operating profit | -0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | -4.0% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Net profit | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS (₹) | -430.00 | 997.86 | 1,597.37 | 358.74 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
TTM is the trailing twelve months to the most recent quarter.
Alivus Life Sciences Ltd balance sheet
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other liabilities | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed assets | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
As reported by the company. Total assets equal total liabilities by construction.
Alivus Life Sciences Ltd cash flow
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Cash from investing | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Cash from financing | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net cash flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free cash flow | -0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO / operating profit | 4,800% | 14% | 61% | 84% | 119% | 71% | 85% | 81% | 93% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Alivus Life Sciences Ltd operating ratios
| Per year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 24% |
| Debtor days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash conversion cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working capital days | -2,059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 194 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Alivus Life Sciences Ltd shareholding pattern
Promoters held 74.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 5.54% and DIIs 7.18%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% |
| FIIs | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.08% | 5.30% | 5.54% |
| DIIs | 4.16% | 4.86% | 5.19% | 5.62% | 5.47% | 7.13% | 7.27% | 7.18% |
| Public | 12.99% | 13.40% | 13.25% | 13.03% | 12.79% | 12.89% | 12.55% | 12.42% |
| No. of shareholders | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 | 1,35,643 | 1,32,748 | 1,27,969 | 1,25,559 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Alivus Life Sciences Ltd corporate filings
- Company update under Regulation 30 with attachment; no financial or operational details disclosedCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd issued a regulatory update referencing an attachment, with no…
Read the full analysis - Alivus Life Sciences Limited acquires 9.21% stake in Torrent Urja 19 Private Limited to enhance renewable energy capacity and meet regulatory captive power requirementsCompany Updatehigh impact
Cruxal's analysis: Alivus Life Sciences Limited has announced the acquisition of a 9.21% equity stake in…
Read the full analysis - Alivus Life Sciences Ltd incorporates wholly owned subsidiary in BrazilCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has formally incorporated a new wholly owned subsidiary in…
Read the full analysis - Alivus Life Sciences Ltd announces upcoming investor meetCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has issued an intimation regarding an upcoming investor meet…
Read the full analysis - Alivus Life Sciences Limited Concludes 15th AGM; Shareholders Approve Final Dividend of INR 5 per Equity ShareAGM/EGMlow impact
Cruxal's analysis: Alivus Life Sciences Limited has successfully concluded its 15th Annual General Meeting…
Read the full analysis - Alivus Life Sciences Ltd announces upcoming investor meetCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has filed an intimation regarding an upcoming analyst/investor…
Read the full analysis - Alivus Life Sciences Ltd announces investor meet intimationCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has filed an intimation regarding an upcoming analyst/investor…
Read the full analysis - Alivus Life Sciences Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has issued a formal intimation regarding an upcoming…
Read the full analysis - Alivus Life Sciences to acquire 76% stake in IQGenX Pharma for 9.12 crore to bolster CDMO and formulation capabilitiesCompany Updatehigh impact
Cruxal's analysis: Alivus Life Sciences Limited has announced the acquisition of a 76% majority stake in…
Read the full analysis - Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma for INR 9.12 crore to bolster CDMO capabilitiesCompany Updatemedium impact
Cruxal's analysis: Alivus Life Sciences Limited has announced the acquisition of a 76% controlling stake in…
Read the full analysis - Alivus Life Sciences Ltd announces upcoming analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has filed an intimation regarding a scheduled meeting with…
Read the full analysis - Alivus Life Sciences Ltd announces 15th Annual General Meeting and E-Voting detailsCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has published a newspaper advertisement regarding the notice of…
Read the full analysis - Alivus Life Sciences Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Alivus Life Sciences Ltd has submitted its Business Responsibility and Sustainability…
Read the full analysis - Alivus Life Sciences Ltd files Integrated Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Alivus Life Sciences Ltd has submitted its Integrated Annual Report for the financial…
Read the full analysis - Alivus Life Sciences Limited Announces 15th AGM for September 8, 2026, Proposes Final Dividend of INR 5 Per ShareAGM/EGMlow impact
Cruxal's analysis: Alivus Life Sciences Limited has scheduled its 15th Annual General Meeting for September…
Read the full analysis - Alivus Life Sciences Ltd announces scheduled investor meetCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has filed an intimation regarding an upcoming investor meet. The…
Read the full analysis - Alivus Life Sciences Ltd schedules analyst and investor meetingCompany Updatelow impact
Cruxal's analysis: Alivus Life Sciences Ltd has issued an intimation regarding an upcoming analyst and…
Read the full analysis - Alivus Life Sciences Q1 FY27 Earnings: Strong Margin Expansion and Non-GPL Growth Offset GPL WeaknessCompany Updatehigh impact
Cruxal's analysis: Alivus Life Sciences reported Q1 FY27 revenue of 640 crore, a 6.4% YoY growth, driven by…
Read the full analysis - Alivus Life Sciences Limited Announces 15th Annual General Meeting (AGM) for September 8, 2026Company Updatelow impact
Cruxal's analysis: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has issued a…
Read the full analysis - Alivus Life Sciences Limited Announces 15th AGM Date and Record Date for Final Dividend of INR 5.00 per ShareAGM/EGMlow impact
Cruxal's analysis: Alivus Life Sciences Limited has scheduled its 15th Annual General Meeting for September…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.